Zogenix’ Acquisition of Modis Therapeutics Completes

12:28 EDT 9 Sep 2019 | Investing News Network

Zogenix (NASDAQ:ZGNX) has announced its acquisition of Modis Therapeutics has completed and that it has added MT1621 to its late-stage development pipeline. As quoted in the press release: MT1621 is a novel investigational deoxynucleoside substrate enhancement therapy for the treatment of Thymidine Kinase 2 deficiency (TK2d), an inherited mitochondrial DNA depletion disorder that predominantly affects … Continued

The post Zogenix’ Acquisition of Modis Therapeutics Completes appeared first on Investing News Network.

Original Article: Zogenix’ Acquisition of Modis Therapeutics Completes


More From BioPortfolio on "Zogenix’ Acquisition of Modis Therapeutics Completes"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...